ReVita-9 begins in a medical research facility. The virus was originally engineered as a regenerative therapy for soldiers and trauma patients. A containment breach occurs when one of the test subjects—still conscious despite failed termination—bites a technician. Within hours, the technician collapses, and the virus silently incubates inside their body.
Day 1–2: A cluster of patients in the nearby hospital present with unusual symptoms: violent tremors, delirium, rapid tissue necrosis followed by spontaneous “recovery.”
Medical staff misdiagnose it as a novel hemorrhagic fever. Quarantine is ordered, but by then, several staff have already been bitten.
Rumors spread of patients “dying” and then waking up hours later.
Day 3–7: First confirmed violent incidents emerge: infected individuals assaulting others, seemingly impervious to pain. Police treat cases as drug-fueled psychosis until officers are bitten and turn within 24 hours.
Panic erupts on social media. Videos circulate of half-decayed bodies chasing down bystanders. Authorities begin enforcing curfews and roadblocks, but evacuation attempts only accelerate the spread.
Airports become flashpoints: an infected passenger boards a flight before symptoms fully manifest, exporting ReVita-9 internationally.
Week 2–4: Governments attempt to establish green zones (fortified safe areas) while deploying military units to burn out infected zones.
Traditional anti-viral treatments fail. Attempts at vaccine development are complicated by the virus’s mutability.
The infected now outnumber healthy survivors in several cities. ReVita-9 proves airborne under certain conditions, spreading in enclosed spaces like subways and shelters.
Martial law is declared, but desertions rise as soldiers witness comrades reanimating.
Month 2 onward:
Megacities collapse into chaos, their infrastructure gutted by fire and looting.
Communication networks fragment—radio chatter from survivors replaces organized broadcasts.
Isolated survivor enclaves emerge in rural or fortified areas, scavenging supplies.
The infection curve plateaus only because there are fewer living hosts left to infect.
ReVita-9 mutates into “strains,” some creating faster, more aggressive variants of the infected, others resulting in hulking, tumor-laden monstrosities.